Literature DB >> 28646568

Blink R1 latency utility in diagnosis and treatment assessment of polyradiculoneuropathy-organomegaly-endocrinopathy-monoclonal protein-skin changes and chronic inflammatory demyelinating polyradiculoneuropathy.

Wei Wang1,2, William J Litchy1, Michelle L Mauermann1, P James B Dyck1, Angela Dispenzieri3, Jay Mandrekar4, Peter J Dyck1, Christopher J Klein1.   

Abstract

INTRODUCTION: In polyradiculoneuropathy-organomegaly-endocrinopathy-monoclonal protein-skin changes (POEMS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), limb nerve conduction studies (NCSs) are limited in identifying demyelination and in detecting treatment effects in severely affected patients. Blink R1 latency may improve these assessments.
METHODS: POEMS and CIDP patients who had undergone NCS and blink reflex were identified. Correlations among R1 latency, limb NCS, and neuropathy impairment scores (NIS) were compared.
RESULTS: Among 182 patients (124 POEMS, 58 CIDP) who were identified, R1 prolongation (>13 ms) occurred in 64.3% (65.3% POEMS, 62.1% CIDP). R1 prolongation correlated with more severely affected NCS in both POEMS (ulnar CMAP 2.6 mV vs. 4.5 mV, P = 0.001) and CIDP (2.0 mV vs. 6.1 mV, P < 0.001). In severely affected patients (ulnar CMAP ≤0.5 mV [10%:18/182]), R1 (>13 ms) helped establish demyelination. In 31 patients (16 POEMS, 15 CIDP), the R1 latency changes were concordant with NIS changes in 94% of patients with POEMS and 60% of patients with CIDP. DISCUSSION: Blink R1 latencies are valuable in defining demyelination and detecting improvement in severely affected POEMS and CIDP patients. Muscle Nerve 57: E8-E13, 2018.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  CIDP; POEMS; blink reflex; nerve conduction study; neuropathy

Mesh:

Year:  2017        PMID: 28646568     DOI: 10.1002/mus.25731

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  2 in total

1.  Clinical and electrophysiological profiles in early recognition of polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes syndrome.

Authors:  Qin Wang; Peng Liu; Li-Li Ji; Shuai Wu; Guo-Dong Feng; Xin Wang; Ji-Hong Dong
Journal:  Chin Med J (Engl)       Date:  2019-07-20       Impact factor: 2.628

Review 2.  Anti-Neurofascin 155 Antibody-Positive Chronic Inflammatory Demyelinating Polyneuropathy/Combined Central and Peripheral Demyelination: Strategies for Diagnosis and Treatment Based on the Disease Mechanism.

Authors:  Jun-Ichi Kira
Journal:  Front Neurol       Date:  2021-06-10       Impact factor: 4.003

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.